Nature Medicine ✓
@NatureMedicine · New York - London · joined 26 Mar 2009
Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians.
358 207Followers
257Following
12 887Posts total
83.7KViews on collected posts
Latest posts
Looking for new posts…
New studies provide evidence on performance, safety & implementation of the #Galleri multi-cancer early detection test, underscoring the next challenge: demonstrating population-level benefit.
Catherine Marinac & colleagues @DanaFarber discuss the data:
https://t.co/VuqPIottCc
6.7K views · 17 likes
· 11 reposts · 3 replies
Open on X →
Integrating numerous multimodal, patient-level biomarkers enhances the prediction of #cancer #immunotherapy response, but generalizability is still a challenge.
News & Views from Raquel Perez-Lopez, Mireia Crispin-Ortuzar @CRUKCamCentre @VHIO
https://t.co/USfT8IdFZK
7.9K views · 14 likes
· 4 reposts · 5 replies
Open on X →
Trials of selective #KRASG12D inhibitors show promise in advanced cancers with G12D mutations, signaling a major shift in the treatment landscape — with potential applications across tumor types and disease stages
News & Views from Jennifer Knox et al.
https://t.co/Rt6DS9VrWW
10K views · 19 likes
· 10 reposts · 3 replies
Open on X →
⚡ Our September issue is live! Featuring new research on #epigenetic clocks, #measles transmission, #preeclampsia, #AI for retinal disease diagnosis, #iPSCs for heart failure and much more including Reviews, News and Opinion.
Read it here: https://t.co/EfJG4ky54j https://t.co/Y3
7.8K views · 29 likes
· 10 reposts · 5 replies
Open on X →
@NatureMedicine Combination therapy is exactly where context matters. The value of one intervention changes when you account for the others and for the patient’s trajectory.
5 views · 0 likes
· 0 reposts · 0 replies
Open on X →
Presented at #ESCCongress: Combining direct oral anticoagulants with powerful P2Y12 inhibitors in atrial fibrillation and acute coronary syndrome patients shows higher bleeding risk without lower ischemic events, compared to using clopidogrel and aspirin.
https://t.co/UOkBurQcP5
6.1K views · 12 likes
· 3 reposts · 2 replies
Open on X →
As presented at the 2026 #ESCCongress: A secondary analysis of the CARDIOTTRansform trial revealed that eplontersen benefited patients with transthyretin amyloid cardiomyopathy who were not on stabilizers, but not those who were.
https://t.co/MRGQqHPH1o
9.9K views · 4 likes
· 3 reposts · 0 replies
Open on X →
A cross-trial analysis of data from 38,753 participants across 9 trials estimates effects of comprehensive medical therapy for heart failure on blood pressure, kidney function, & potassium levels, potentially guiding safer therapy initiation. #ESCCongress
https://t.co/e6n2xu0nYB
10.2K views · 29 likes
· 11 reposts · 1 replies
Open on X →
A trial on #psilocybin-assisted therapy for treatment-resistant #depression shows promising adherence & safety. It also raises questions about access, treatment locations and standards for sustainability. News & Views from Liliana Galindo & colleagues: https://t.co/bnyrnxL0Wb
9.6K views · 36 likes
· 9 reposts · 2 replies
Open on X →
Learn more about the Nature Medicine Commission on Brain Health for Economic Resilience: https://t.co/1BWg6S48fS
@neuronman @HarrisAEyre @rym_ayadi @EMEAorg @mtdespo @DrRKDhamija @ekkehardernst @cogscimon @burcin_ikiz @AgustinMIbanez @CristineLegare @PierLuigiSacco @JochenReiser
2.8K views · 7 likes
· 3 reposts · 0 replies
Open on X →
We are delighted to announce the @NatureMedicine #Commission on Brain Health for Economic Resilience. This a two-year global, transdisciplinary effort to define, measure, and advance #BrainHealth and cognitive capacity as foundational drivers of #EconomicResilience.
See https://
12.7K views · 58 likes
· 21 reposts · 8 replies
Open on X →
Against accounts of the same size
9 posts from the last 90 days, next to the 100K–1M follower range. shown widely, but few of those viewers react.
Median views7 894this account5 983median for 100K–1M
Reach, %2.20%this account1.49%median for 100K–1M
Engagement, %0.32%this account0.93%median for 100K–1M
| Metric | This account | Median for 100K–1M | Ratio |
|---|---|---|---|
| Median views per post | 7 894 | 5 983 | 1.32× |
| Reach (views ÷ followers) | 2.20% | 1.49% | 1.48× |
| Engagement rate | 0.32% | 0.93% | 0.34× |
Others in this range → Compare with another account → How these benchmarks are built →
Growth & engagement
How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.
Views per post
12.7K10 Jun
2.8K
2512 Jun
9.6K28 Aug
10.2K31 Aug
9.9K
6.1K
52 Sep
7.8K17 Sep
10K
7.9K
6.7K23 Sep
Last 12 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.
Engagement rate per post
0.70%10 Jun
0.42%
0.00%12 Jun
0.50%28 Aug
0.40%31 Aug
0.07%
0.28%
0.00%2 Sep
0.57%17 Sep
0.32%
0.29%
0.48%23 Sep
Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 0.93%.
What the audience does
Likes56.2%225 in total
Reposts21.2%85 in total
Replies7.2%29 in total
Quotes1.5%6 in total
Bookmarks13.8%55 in total
Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.
The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.
Similar accounts
Paracetamor ✓
@paracetamor
716.2K followers
· 75.7K posts
Milwaukee Brewers
@Brewers
716.1K followers
· 71.5K posts
fiorella mannoia
@FiorellaMannoia
716K followers
· 21.2K posts
Michael Irvin ✓
@michaelirvin88
715.9K followers
· 9.6K posts
Paulo Costa ✓
@BorrachinhaMMA
715.9K followers
· 13.6K posts
BSE India ✓
@BSEIndia
715.7K followers
· 33.6K posts
Volkswagen
@VW
715.6K followers
· 37K posts
Grande Fratello ✓
@GrandeFratello
715.6K followers
· 33.1K posts